View in EDS

Evaluating methylphenidate as a potential treatment for cocaine use disorder: a propensity score-matched study.

Saved in:
Bibliographic Details
Title: Evaluating methylphenidate as a potential treatment for cocaine use disorder: a propensity score-matched study.
Authors: Magagnoli, Joseph (AUTHOR), Cummings, Tammy H. (AUTHOR), Wyatt, Michael D. (AUTHOR), Shtutman, Michael (AUTHOR), Sutton, S. Scott (AUTHOR)
Source: American Journal of Drug & Alcohol Abuse. 2026, Vol. 52 Issue 2, p219-229. 11p.
Subjects: Methylphenidate, Cocaine-induced disorders, Substance abuse treatment, Cohort analysis, Dopamine uptake inhibitors, Veterans' health, Bupropion, Propensity score matching, United States. Dept. of Veterans Affairs
Abstract: Background: Cocaine's psychoactive effects arise primarily from dopamine transporter (DAT) inhibition. Prior trials suggest methylphenidate, a DAT inhibitor with pharmacologic overlap with cocaine, may reduce cocaine use, but real-world data are limited. Objectives: To evaluate whether methylphenidate exposure is associated with reduced likelihood of subsequent positive cocaine screens among veterans treated within the VA healthcare system. Methods: This retrospective cohort study used the Veterans Affairs Informatics and Computing Infrastructure (VINCI) to identify 109,608 patients with a positive cocaine screen. Among these patients 109,105 (103,535 male) had no methylphenidate exposure and 503 (458 male) were prescribed methylphenidate. Patients with methylphenidate were compared to unexposed patients and to an active comparator, bupropion. Baseline covariates included age, sex, ADHD, psychiatric and substance use disorders and comorbidities. Propensity score matching balanced groups and logistic regression models with generalized estimating equations estimated adjusted odds ratios (ORs) for a positive cocaine screen during one-year follow-up. Results: After matching, methylphenidate exposure was associated with lower odds of a follow-up positive cocaine screen compared with no exposure (OR = 0.71, 95% CI 0.51–0.98) and with bupropion (OR = 0.60, 95% CI 0.41–0.87). Conclusion: In this large real-world cohort of US veterans, methylphenidate exposure was significantly associated with a lower likelihood of subsequent cocaine detection. These results suggest that methylphenidate is a viable pharmacologic candidate for addressing cocaine use disorder, demonstrating superior outcomes in this population when compared to no exposure or the use of bupropion. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Background: Cocaine's psychoactive effects arise primarily from dopamine transporter (DAT) inhibition. Prior trials suggest methylphenidate, a DAT inhibitor with pharmacologic overlap with cocaine, may reduce cocaine use, but real-world data are limited. Objectives: To evaluate whether methylphenidate exposure is associated with reduced likelihood of subsequent positive cocaine screens among veterans treated within the VA healthcare system. Methods: This retrospective cohort study used the Veterans Affairs Informatics and Computing Infrastructure (VINCI) to identify 109,608 patients with a positive cocaine screen. Among these patients 109,105 (103,535 male) had no methylphenidate exposure and 503 (458 male) were prescribed methylphenidate. Patients with methylphenidate were compared to unexposed patients and to an active comparator, bupropion. Baseline covariates included age, sex, ADHD, psychiatric and substance use disorders and comorbidities. Propensity score matching balanced groups and logistic regression models with generalized estimating equations estimated adjusted odds ratios (ORs) for a positive cocaine screen during one-year follow-up. Results: After matching, methylphenidate exposure was associated with lower odds of a follow-up positive cocaine screen compared with no exposure (OR = 0.71, 95% CI 0.51–0.98) and with bupropion (OR = 0.60, 95% CI 0.41–0.87). Conclusion: In this large real-world cohort of US veterans, methylphenidate exposure was significantly associated with a lower likelihood of subsequent cocaine detection. These results suggest that methylphenidate is a viable pharmacologic candidate for addressing cocaine use disorder, demonstrating superior outcomes in this population when compared to no exposure or the use of bupropion. [ABSTRACT FROM AUTHOR]
ISSN:00952990
DOI:10.1080/00952990.2026.2614291